Pharma and Life Sciences CFO Jobs in San Francisco

22:14 / pre-close call

The trial forecast improves on Friday and the cash runway shortens before Monday's audit-committee pack

A contract research organisation reports faster site activation. Clinical leadership sees momentum. Finance sees investigator advances, data-management work, central-laboratory volume and a manufacturing deposit arriving earlier than the approved plan. Business development expects a collaboration receipt, but the contract amendment is not signed.

The CFO has seventy-two hours to separate five statements that colleagues are treating as one: the scientific programme is progressing, services have been performed, invoices have arrived, cash is committed, and funding is available. None proves the others. The close must record the best supportable estimate while the board receives a decision runway that does not count unsigned consideration.

A San Francisco pharma finance mandate begins here, not at the next capital raise. The seat owns the system that turns uncertain programme activity into a controlled financial assertion, then explains how that assertion changes choices without pretending to adjudicate science, safety, quality or law.

This page was compiled on 17 August 2026. It identifies no company, asset, study, financing, transaction or vacancy.

Seven-drawer runway

Cash survives only after ownership, access, obligation, timing, evidence, disclosure and reversal are opened separately

The candidate should rebuild one monthly forecast as a decision instrument. Ask which input they refused, which commitment they moved, what the board was told, and how the next actual result changed the model. Spreadsheet fluency without evidence provenance is not CFO proof.

Mandate balance sheet

The CFO cannot own enterprise liquidity until the Charter names every entity that can receive, spend, restrict or promise cash

Map the parent, operating subsidiaries, research entities, intellectual-property owner, IND sponsor, manufacturer, California licensee, collaboration counterparties and any special-purpose or overseas entities. For each, identify bank ownership, payroll, contracts, tax profile, licence, transfer rights, guarantees and board authority.

Then allocate CEO, CFO, controller, treasury, tax, clinical, regulatory, quality, manufacturing, legal, business-development and disclosure decisions. A CFO may consolidate results without having legal access to a balance or professional authority over a clinical estimate. The Charter should expose both boundaries.

Name the first close, first financing decision, first material accrual, first public disclosure and the condition that allows the CFO to stop an unsupported statement. A board seeking a capital-markets personality without granting source access is not offering an accountable finance mandate.

Market zero / no inferred package

Zero authorised Charters support no vacancy, USD reward range, financing calendar or implied company identity

Pharma and Life Sciences CFO Jobs in San Francisco describes a category of work. A Form 8-K, fundraising rumour, licence application, trial record, executive biography or office address does not authorise a search inference.

Reward varies with public status, financing horizon, programme stage, collaboration complexity, manufacturing footprint, international entities, transaction agenda, team, board exposure, location and equity instrument. Those variables do not permit a fabricated benchmark from zero Charters.

Membership pays for assessment, bounded verification and a controlled route to authorised mandates. It creates no rank, introduction, interview, capital endorsement or appointment.

Clinical accrual replay

Sites have treated patients, the CRO portal is incomplete and the quarter can be closed only by estimating work nobody in finance observed

Give the candidate a synthetic multi-site study with contracted unit rates, start-up fees, pass-through costs, screen failures, enrolled participants, monitoring visits, data work, amendments and delayed invoices. Clinical operations holds several activity sources, none designed as an accounting subledger.

The CFO should define the source hierarchy, cut-off date, service population, estimate method, currency, amendment treatment, control owner, reviewer, variance threshold and true-up. Clinical colleagues validate activity within their remit. Accounting owners determine the conclusion. Finance should not ask a project manager to certify a number whose population and assertion have never been defined.

Now reveal that one high-enrolling site reported late and a CRO change order remains disputed. Observe whether the candidate updates the best estimate, preserves the dispute separately and explains the forecast consequence without using the close to settle a commercial argument.

Milestone four-way split

The partner wires forty million dollars and cash, revenue, tax and programme freedom move in four different directions

A fictional collaboration pays on execution, requires technology transfer, funds defined research and carries later development options. Management wants the receipt added to revenue, runway and discretionary programme capacity on the same day.

The CFO should build four independent records. Treasury confirms legal recipient, settlement, restrictions and transfer access. Accounting analyses rights, obligations, consideration and recognition under applicable guidance. Tax specialists determine entity and timing consequences. Programme governance establishes which work and decisions remain committed.

Then introduce a termination right, a disputed deliverable and an affiliate that performs part of the work. Ask what can be stated before contract, accounting, tax and operational analysis converge. The strongest candidate neither withholds useful cash information nor turns receipt into an unsupported earnings or freedom claim.

California credit shadow bridge

A research credit can be generated, carried, limited, assigned or elected into a refund schedule and still fund none of next month's trial invoices

The California Franchise Tax Board's 2025 Form 3523 instructions describe a research credit for qualifying activity, including California requirements and special biopharmaceutical basic-research provisions. They also describe a five-million-dollar application limitation for taxable years beginning from 2024 through 2026 and an election concerning amounts disallowed by that limitation. Actual eligibility and treatment require current tax analysis.

Give the candidate qualified-research work across a parent, disregarded entity and acquired subsidiary. The model shows a large credit asset and treats it as near-term financing. Ask for the taxpayer, controlled-group computation, California activity, documentation, generated amount, usable amount, carryover, assignment, election, cash-tax effect and expected date.

A technically valid tax attribute is not cash access. Finance leadership means preserving its value while preventing fundraising materials or programme plans from spending it twice.

Adjusted-runway hearing

The board removes recurring research spend from adjusted loss because each individual programme can theoretically be stopped

SEC staff non-GAAP guidance states that excluding normal, recurring cash operating expenses necessary to operate a registrant's business can be misleading. It also warns about inconsistent treatment and measures that apply individually tailored recognition or measurement principles.

Provide a fictional company that excludes programme costs labelled strategic, stock compensation, transaction costs and a recurring manufacturing-reservation fee. The CFO should begin with the most directly comparable GAAP measure, define every adjustment, preserve period consistency, identify cash effects and explain which spend is normal in the actual business model.

Runway can be presented as a management scenario when clearly defined and properly controlled. It cannot quietly change accounting or erase the cost of operating the declared strategy. Ask whether the candidate would withdraw the metric, redesign it or add context, and who must approve the decision.

Licence-transfer cash gate

The acquisition closes on Friday and the California manufacturing entity, facility address and release plan do not move by purchase-agreement arithmetic

CDPH's Food and Drug Branch publishes a drug-manufacturing licence application for a new applicant, renewal, ownership change and relocation. That does not establish the duty for every transaction, but it makes legal entity and facility facts a finance dependency that should be resolved before the close model assumes uninterrupted operations.

Use a synthetic acquisition with a licensed California facility, transition services, inventory in different quality states, a contract manufacturer and a planned legal-entity merger. The CFO maps purchase consideration, working capital, licence path, inventory ownership, release authority, transfer restrictions, duplicated cost, delay contingency and disclosure.

Regulatory, quality and legal owners determine whether and how operations may continue. Finance funds the compliant route, values uncertainty and stops the board from treating a signed agreement as proof that product, licence and cash can transfer on the same date.

Nine-piece finance proof set

Build a CFO dossier from reversals and reconciliations, not the size of the financing printed beside a former employer

For each claim, state the legal entity, assertion, source population, method, professional boundary, disagreement, decision, aggregate outcome, subsequent true-up and residual weakness. Quantify only where an authorised, de-identified basis survives.

References should speak to conduct under pressure: whether the candidate corrected favourable information, protected accounting independence, kept clinical and quality judgments with qualified owners, and made an estimate reproducible without themselves.

Questions before a quiet move

Direct answers for finance leaders evaluating an unadvertised Bay Area life sciences mandate

Two-close acceptance rehearsal

Reperform the inherited quarter and the next decision close before accepting responsibility for the runway

First map every parent, subsidiary, research entity, intellectual-property owner, sponsor, manufacturer, California licensee and collaboration counterparty. Reconcile legal ownership, bank access, guarantees, tax attributes, contracts, licences and transfer authority.

Reperform one clinical accrual from contract and activity evidence through estimate, review, posting, disclosure, payment and later true-up. Sample a late site, disputed change order, foreign-currency item and service performed without an invoice.

Trace one collaboration receipt through legal right, treasury, accounting, tax, programme obligation and external narrative. Identify what remains conditional, restricted or reversible. Do the same for one manufacturing deposit and inventory position.

Rebuild runway by irreversible decision date rather than cash-zero month. Stress a slower enrolment case, earlier manufacturing commitment, delayed financing and failed milestone. Separate actions management controls from scientific, regulatory, market and counterparty outcomes it does not.

Review Item 303 and other applicable disclosure controls with securities counsel, auditors and designated owners. Reperform a non-GAAP measure and verify consistent definition, GAAP reconciliation, cash consequences and balanced context.

Test the California research-credit bridge and drug-manufacturing licence dependencies with qualified tax, regulatory, quality and legal teams. Do not treat an asset balance or application as cash or permission.

Agree the CFO's information rights, controller and treasury capacity, disclosure committee, audit-committee access, close calendar, stop authority and first ninety-day docket. Complete accounting, audit, securities, tax, regulatory, identity, reference, background and compensation diligence before resignation.